$CLBT

Hogan Thomas E. sold $1.6M of CLBT

Hogan Thomas E. (Chief Executive Officer) sold 103,188 shares of Cellebrite DI Ltd. (CLBT) at $15.76 ($1.63M total) on 2026-07-02.

Original reporting
SEC EDGAR · Hogan Thomas E.
Published Jul 7, 2026, 11:29 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLBT
Neutral
high confidence
Mentioned
$CLBT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity, but the text contains no new guidance, contracts, litigation, or operational developments.

02

Market read

A $1.63M CEO open-market sale is disclosed; likely sentiment-only unless corroborated by other new catalysts.

03

What to watch

No 10b5-1 plan is stated, but the article also provides no reason for the sale or any concurrent buying/selling pattern beyond this single transaction.

Relevance 6/10Novelty 5/10Timing: Filed July 7; reflects sale executed July 2.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Cellebrite DI Ltd. (CLBT).

Company-level read

Ticker impact

$CLBTNeutralHigh confidence
Context

Cellebrite CEO Hogan Thomas E. sold 103,188 shares in an open-market transaction worth about $1.63M, per Form 4 filed July 7.

Expected impact

Low near-term impact; any reaction is likely limited unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider sale with no 10b5-1 plan and no accompanying operational/regulatory update in the text.

Market effects

Minimal—this is an issuer-specific insider transaction with no sector-wide signal provided.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or liquidity needs; without additional context, it may not indicate deteriorating fundamentals.

Key entities

  • Cellebrite DI Ltd.

    Public company subject of the Form 4 insider sale disclosure.

  • Hogan Thomas E.

    CEO and officer/director who sold shares via open-market sale.

Related articles